Short-term rosuvastatin treatment for the prevention of contrast-induced acute kidney injury in patients receiving moderate or high volumes of contrast media: A sub-analysis of the TRACK-D study

Chinese Medical Journal

Volumn 128, Issue 6, 2015, Pages 784-789

  Zhang, Jian ^a   Li, Yi ^a   Tao, Gui Zhou ^b   Chen, Yun Dai ^c   Hu, Tao Hong ^c   Cao, Xue Bin ^d   Jing, Quan Min ^a   Wang, Xiao Zeng ^a   Ma, Ying Yan ^a   Wang, Geng ^a   Liu, Hai Wei ^a   Wang, Bin ^a   Xu, Kai ^a   Li, Jing ^a   Deng, Jie ^a   Han, Ya Ling ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b JINZHOU MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d The 252 Hospital of Chinese PLA   (China)

Author keywords

Chronic kidney disease; Contrast induced acute kidney injury; Rosuvastatin

Indexed keywords

C REACTIVE PROTEIN; CREATININE; IODIXANOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; CONTRAST MEDIUM; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ACUTE KIDNEY FAILURE; ADULT; ARTERIOGRAPHY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DEATH; EVENING DOSAGE; FEMALE; HEART FAILURE; HEMOFILTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ACUTE KIDNEY INJURY; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED;

ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; FEMALE; FLUOROBENZENES; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84929072067     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.4103/0366-6999.152620     Document Type: Article

References (21)

1. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010;122:2451-5.
2. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;52:409-16.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
4. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: A clinical and evidence-based approach. Circulation 2006;113:1799-806.
5. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014;63:62-70.
6. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol 2014;63:71-9.
7. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D’Ambrosio A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty – Contrast-induced nephropathy] trial. Am J Cardiol 2011;108:1-7.
8. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61:711-4.
9. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial – A randomized controlled study. Am Heart J 2008;155:499.e1-8.
10. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44:1393-9.
11. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-6.
12. Muñoz MA, Maxwell PR, Green K, Hughes DW, Talbert RL. Pravastatin versus simvastatin for prevention of contrast-induced nephropathy. J Cardiovasc Pharmacol Ther 2011;16:376-9.
13. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol 2004;62:273-8.
14. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med 2005;118:843-9.
15. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619.
16. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
17. Deo SH, Fisher JP, Vianna LC, Kim A, Chockalingam A, Zimmerman MC, et al. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol 2012;303:H377-85.
18. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:1896-901.
19. Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-Pascuala R, Hernández G, Díaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
20. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering – Are they clinically relevant? Eur Heart J 2003;24:225-48.
21. Wang XC, Fu XH, Wang YB, Jia XW, Wu WL, Gu XS, et al. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: Role of the ratio of contrast medium volume to estimated glomerular filtration rate. Chin Med J 2011;124:892-6.